ChemoCentryx soars 109% as Amgen agrees to buy for $3.7B in cash

Aug. 04, 2022 8:44 AM ETAmgen Inc. (AMGN)AMGNBy: Dulan Lokuwithana, SA News Editor8 Comments

word m and a made with wood building blocks, stock image

Maks_Lab/iStock via Getty Images

  • Amgen (NASDAQ:AMGN) has agreed to buy ChemoCentryx (CCXI), a drug developer focused on autoimmune disorders, for $3.7B in cash, the companies announced on Thursday in an emailed statement.
  • After a brief trading pause, ChemoCentryx (

Recommended For You

Comments (8)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.